✦ LIBER ✦

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

✍ Scribed by Mohammad Azam; Robert R. Latek; George Q. Daley

Book ID: 117269463
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 1020 KB
Volume: 112
Category: Article
ISSN: 0092-8674
DOI: 10.1016/s0092-8674(03)00190-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Molecular and chromosomal mechanisms of

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

✍ Hochhaus, A; Kreil, S; Corbin, A S; La Rosée, P; Müller, M C; Lahaye, T; Hanfste 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 177 KB

Clinical Resistance to STI-571 Cancer Th

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

✍ Gorre, M. E. 📂 Article 📅 2001 🏛 American Association for the Advancement of Scienc 🌐 English ⚖ 474 KB

Mechanisms of resistance imatinib (STI57

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients

✍ Ellen Weisberg; James D. Griffin 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 215 KB

Changes associated with the development

Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein

✍ Barbara Scappini; Simona Gatto; Francesco Onida; Clara Ricci; Vladimir Divoky; W 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 1 views

## Abstract ## BACKGROUND Although various mechanisms have been recognized as being associated with the development of resistance to imatinib mesylate in vitro and in clinical situations, their relative significance and contributions remain poorly understood, as is the sequence of events leading t

Mechanisms of resistance to imatinib (ST

Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents

✍ Geoffrey W. Krystal 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Imatinib mesylate (STI571) abrogates the

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair

✍ Ireneusz Majsterek; Tomasz Sliwinski; Tomasz Poplawski; Dariusz Pytel; Michal Ko 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 233 KB